Stem Cell Transplant & Cellular Therapies Symposium: Improving Access & Equity to Evolving Therapies

When:  Oct 1, 2021 from 08:30 to 13:20 (CT)
Join clinical leaders from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Boston Children’s Hospital in the Transplant & Cell Therapies Annual Symposium: Improving Access and Equity to Evolving Therapies.

This activity is intended for local referring providers, nurses, PAs, pharmacists, payer representatives, case managers.

Upon completion of this activity, participants will be able to:
  • Demonstrate comprehension of the referral process and care coordination between the community oncologist and the transplant team, including the pre-transplant workup process.
  • Identify common and uncommon post-treatment toxicities post-treatment and differentiate between various common, chronic, and advanced infections post-treatment.
  • Demonstrate comprehension of the use of haploidentical transplantation and its practicality.
  • Review other non-infectious concerns that may present during short-term and long-term recovery from treatment.
  • Categorize common toxicities during CAR T-cell treatment 6. Discuss latest therapies in research and clinical practiceMass General Brigham is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Welcome, Introduction to Today's Session
  • Amy Emmert, Executive Director for Cellular Therapy External Affairs
  • Kidest Mequanent, Senior Program Manager, Cellular Therapies
Panel Discussion: Health Equity/Access to Care
  • Moderator: Kidest Mequanent
  • Panelists: Desiree Otenti, NP; Dana Yoo, MD; Ludmila Svoboda, RN, BSN, MA, OCN
Pediatric Perspective on Access to Care for Stem Cell Transplant
  • Leslie Lehmann, MD
The Dynamic and Emerging Role of Cellular Therapies: Autologous Transplant, CAR-T, NK Cells, Sickle Cell and Thalassemia
  • Moderator: Julie Porter, MSc, Vice President of Cellular Therapy Operations
  • Paneilsts: Rizwan Romee, MD; Caron Jacobson, MD; Clifton Mo, MD; Joseph Antin, MD
Infectious Disease in Transplant: Challenges and Barriers to Treatment
  • Sarah Hammond, MD
After Transplant: Dana-Farber's Allogeneic Survivorship Program, Long-Term Follow-Up, and the Nursing Perspective
  • Panelists: Corey Cutler, MD, MPH, FRCPC; Abigail Ciampa, NP

Mass General Brigham designates this live activity for a maximum of 4 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commensurate nursing CEU and PA CME credits will be sought.